López-González GJD, Aguilar JMP, Rosales CA

Language: Spanish
References: 11
Page: 99-103
PDF size: 201.85 Kb.

ABSTRACT

Complications at bone and cardiovascular levels characterize mineral-bone disorder associated with chronic kidney disease (CKD-MBD). It occurs in nephropathic patients with poor adherence to treatment. We present a clinical case that suffered two complications associated with this entity: osteitis fibrosa cystica and stroke due to calcium embolism, which we describe. With proper management, its incidence is drastically reduced, which is why close surveillance and active followup of patients is essential.

REFERENCES

1. Moe S, et al. Definition, evaluation, and classification ofrenal osteodystrophy: a position statement from kidneydisease: Improving Global Outcomes (KDIGO).Kidney Int, 69 (2006), pp. 1945-1953.

2. De Francisco AL, Gillespie IA, Gioni I, Floege J,Kronenberg F, Marcelli D, Wheeler DC, FroissartM, Drueke TB; ARO Steering CommitteeCllaborators. Anti-parathyroid treatment effectivenessand persistence in incident haemodialysis patientswith secondary hyperparathyroidism. Nefrologia.2016;36(2):164-75. doi: 10.1016/j.nefro.2015.10.006.Epub 2015 Dec 3. PMID: 26654696.

3. Covic A, et al. Systematic review of the evidenceunderlying the association between mineralmetabolism disturbances and risk of all-causemortality, cardiovascular mortality, andcardiovascular events in chronic kidney disease.Nephrology, Dialysis, Transplantation, Volume 24,Issue 5, May 2009, Pages 1506–1523, https://doi.org/10.1093/ndt/gfn613

4. Slinin, Yelena; Foley, Robert N.; Collins, Allan.Calcium, Phosphorus, Parathyroid Hormone, andcardiovascular disease in Hemodialysis Patients:The USRDS Waves 1, 3, and 4 Study. Journal of theAmerican Society of Nephrology 16(6):p 1788-1793,June 2005. | DOI: 10.1681/ASN.2004040275

5. Covic A, Rastogi A. Hyperphosphatemia in patientswith ESRD: assessing the current evidence linkingoutcomes with treatment adherence. BMC Nephrol,14 (2013), p. 153

6. Pazianas M, Miller PD. Osteoporosis and ChronicKidney Disease-Mineral and Bone Disorder(CKD-MBD): Back to Basics. Am J Kidney Dis. 2021Oct;78(4):582-589. doi: 10.1053/j.ajkd.2020.12.024.Epub 2021 Mar 25. PMID: 33774081.

7. Mishra SK, Agarwal G, Kar DK, Gupta SK, MithalA, Rastad J. Unique clinical characteristics ofprimary hyperparathyroidism in India. Br J Surg.2001;88:708-14

8. Doufekias E., Segal A.Z., Kizer J.R.: Cardiogenic andAortogenic Brain Embolism. J Am Coll Cardiol 2008;51: pp. 1049-1059.

9. Pasch A., Block G.A., Bachtler M., Smith E.R., Jahnen-Dechent W., Arampatzis S., et. al.: Blood CalcificationPropensity Cardiovascular Events, and Survival inPatients Receiving Hemodialysis in the EVOLVETrial. Clin J Am Soc Nephrol 2017; 12: pp. 315.

10. 10) Slinin Y, et al. Calcium, phosphorus, parathyroidhormone, and cardiovascular disease in hemodialysispatients: the USRDS waves 1, 3, and 4 study. J Am SocNephrol, 16 (2005), pp. 1788-1793

11. Torregrosa JV, Bover J, Rodríguez Portillo M,González Parra E, Dolores Arenas M, Caravaca F,González Casaus ML, Martín-Malo A, Navarro-González JF, Lorenzo V, Molina P, Rodríguez M,Cannata Andia J. Recommendations of the SpanishSociety of Nephrology for the management of mineraland bone metabolism disorders in patients withchronic kidney disease: 2021 (SEN-MM). Nefrologia(Engl Ed). 2023 May 16:S2013-2514(23)00057-3. doi:10.1016/j.nefroe.2023.03.003. Epub ahead of print.PMID: 37202281.